Vanguard Group
HPTX

Vanguard Group’s HYPERION THERAPEUTICS INC COM STK (DE) HPTX Stock Holding History

Vanguard Group’s Portfolio HPTX Stock Details HPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-416,111
Closed -$19.1M – 4237
2015
Q1 		$19.1M Buy
416,111
+54,741
+15% +$1.64M ﹤0.01% 2345
2014
Q4 		$8.67M Buy
361,370
+15,967
+5% +$360K ﹤0.01% 2604
2014
Q3 		$8.71M Buy
345,403
+22,128
+7% +$549K ﹤0.01% 2558
2014
Q2 		$8.44M Buy
323,275
+7,515
+2% +$193K ﹤0.01% 2580
2014
Q1 		$8.15M Buy
315,760
+37,046
+13% +$1M ﹤0.01% 2584
2013
Q4 		$5.63M Buy
278,714
+36,952
+15% +$870K ﹤0.01% 2732
2013
Q3 		$6.32M Buy
241,762
+50,997
+27% +$1.28M ﹤0.01% 2616
2013
Q2 		$4.2M Buy
+190,765
New +$4.18M ﹤0.01% 2760

Vanguard Group's HPTX Position: Q2 2015 in Review

Vanguard Group sold out of HYPERION THERAPEUTICS INC COM STK (DE) (HPTX) in Q2 2015, closing a stake of 416,111 shares — an estimated $19.1M sold.

Vanguard Group first reported a position in HPTX in Q2 2013 and held it in 8 quarters. The position peaked at $19.1M in Q1 2015. 0 funds tracked by Wall St. Rank hold HPTX as of Q2 2015.

  • Vanguard Group reported no remaining HYPERION THERAPEUTICS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Vanguard Group sold 416,111 HYPERION THERAPEUTICS INC COM STK (DE) shares in Q2 2015, an estimated $19.1M.
  • Vanguard Group first reported a position in HYPERION THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Vanguard Group's HYPERION THERAPEUTICS INC COM STK (DE) position peaked at $19.1M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held HYPERION THERAPEUTICS INC COM STK (DE) as of Q2 2015.

Based on Vanguard Group's 13F filing for Q2 2015, filed 13 Aug 2015.